{"name":"Shire","slug":"shire","ticker":"","exchange":"","domain":"shire.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":15160600000,"revenueGrowth":310,"grossMargin":0,"rdSpend":1763300000,"netIncome":4271500000,"cash":472400000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"1959-01-01","label":"Saluron first approved","drug":"Saluron","drugSlug":"hydroflumethiazide","type":"approval","sentiment":"positive"},{"date":"2010-01-01","label":"Vpriv first approved","drug":"Vpriv","drugSlug":"velaglucerase-alfa","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":23,"colorKey":"oncology","drugs":[{"name":"SPD476 (1.2g)","genericName":"SPD476 (1.2g)","slug":"spd476-1-2g","indication":"Unknown","status":"phase_3"},{"name":"ALX-0600","genericName":"ALX-0600","slug":"alx-0600","indication":"Other","status":"phase_2"},{"name":"ALX1-11","genericName":"ALX1-11","slug":"alx1-11","indication":"Other","status":"phase_3"},{"name":"Dynepo","genericName":"Dynepo","slug":"dynepo","indication":"Other","status":"marketed"},{"name":"SPD489","genericName":"SPD489","slug":"spd489","indication":"Other","status":"marketed"},{"name":"C1 Esterase Inhibitor (Human)","genericName":"C1 Esterase Inhibitor (Human)","slug":"c1-esterase-inhibitor-human","indication":"Hereditary angioedema (HAE) Types I and II — acute attack treatment","status":"marketed"},{"name":"C1 esterase inhibitor [human] liquid","genericName":"C1 esterase inhibitor [human] liquid","slug":"c1-esterase-inhibitor-human-liquid","indication":"Hereditary angioedema (HAE) Types I and II — acute attack treatment and prophylaxis","status":"phase_3"},{"name":"C1 inhibitor (human) [C1 INH]","genericName":"C1 inhibitor (human) [C1 INH]","slug":"c1-inhibitor-human-c1-inh","indication":"Hereditary angioedema (HAE) — acute attack treatment","status":"marketed"},{"name":"CINRYZE 1000","genericName":"CINRYZE 1000","slug":"cinryze-1000","indication":"Hereditary angioedema (HAE) — acute attack prevention and treatment","status":"phase_3"},{"name":"CINRYZE 1000 U","genericName":"CINRYZE 1000 U","slug":"cinryze-1000-u","indication":"Hereditary angioedema (HAE) Types I and II — acute attack treatment and prophylaxis","status":"phase_3"},{"name":"CINRYZE 500","genericName":"CINRYZE 500","slug":"cinryze-500","indication":"Hereditary angioedema (HAE) Types I and II — acute attack treatment and prophylaxis","status":"phase_3"},{"name":"CINRYZE 500 U","genericName":"CINRYZE 500 U","slug":"cinryze-500-u","indication":"Hereditary angioedema (HAE) Types I and II — acute attack treatment and prophylaxis","status":"phase_3"},{"name":"Elaprase","genericName":"Elaprase","slug":"elaprase","indication":"Mucopolysaccharidosis, MPS-II","status":"marketed"},{"name":"FST-100","genericName":"FST-100","slug":"fst-100","indication":"Other","status":"phase_2"},{"name":"Fosrenol (Lanthanum Carbonate)","genericName":"Fosrenol (Lanthanum Carbonate)","slug":"fosrenol-lanthanum-carbonate","indication":"Hyperphosphatemia in patients with chronic kidney disease on dialysis","status":"phase_3"},{"name":"HGT-1110","genericName":"HGT-1110","slug":"hgt-1110","indication":"Other","status":"phase_1"},{"name":"MHOS/SHP615","genericName":"MHOS/SHP615","slug":"mhos-shp615","indication":"Growth hormone deficiency in adults","status":"phase_3"},{"name":"PEG 4000","genericName":"PEG 4000","slug":"peg-4000","indication":"Constipation","status":"phase_3"},{"name":"PTH/Calcium","genericName":"PTH/Calcium","slug":"pth-calcium","indication":"Hypoparathyroidism","status":"phase_3"},{"name":"Phosphate Buffer Saline (PBS),","genericName":"Phosphate Buffer Saline (PBS),","slug":"phosphate-buffer-saline-pbs","indication":"Other","status":"phase_3"},{"name":"lumbar puncture","genericName":"lumbar puncture","slug":"lumbar-puncture","indication":"Other","status":"phase_3"},{"name":"rhPTH (1-84)","genericName":"rhPTH (1-84)","slug":"rhpth-1-84","indication":"Hypoparathyroidism","status":"marketed"},{"name":"tedguglutide","genericName":"tedguglutide","slug":"tedguglutide","indication":"Other","status":"phase_1"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":8,"colorKey":"neuroscience","drugs":[{"name":"SPD476","genericName":"SPD476","slug":"spd476","indication":"Treatment-resistant depression","status":"phase_3"},{"name":"SPD503-AM","genericName":"SPD503-AM","slug":"spd503-am","indication":"Attention-deficit/hyperactivity disorder (ADHD)","status":"phase_3"},{"name":"SPD503-PM","genericName":"SPD503-PM","slug":"spd503-pm","indication":"Obsessive-compulsive disorder","status":"phase_3"},{"name":"Vpriv","genericName":"VELAGLUCERASE ALFA","slug":"velaglucerase-alfa","indication":"Chronic non-neuropathic Gaucher's disease","status":"marketed"},{"name":"SPD476 (2.4 g)","genericName":"SPD476 (2.4 g)","slug":"spd476-2-4-g","indication":"Major depressive disorder","status":"phase_3"},{"name":"SPD503 (2 mg)","genericName":"SPD503 (2 mg)","slug":"spd503-2-mg","indication":"Parkinson's disease","status":"phase_3"},{"name":"SPD503 (Guanfacine HCl)","genericName":"SPD503 (Guanfacine HCl)","slug":"spd503-guanfacine-hcl","indication":"Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents","status":"phase_3"},{"name":"TED","genericName":"TED","slug":"ted","indication":"Attention-deficit/hyperactivity disorder (ADHD)","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"rare","drugs":[{"name":"Delayed and extended release mesalazine","genericName":"Delayed and extended release mesalazine","slug":"delayed-and-extended-release-mesalazine","indication":"Ulcerative colitis (induction and maintenance of remission)","status":"phase_3"},{"name":"MMX Mesalamine","genericName":"MMX Mesalamine","slug":"mmx-mesalamine","indication":"Induction of remission of mild to moderate ulcerative colitis","status":"marketed"},{"name":"MMX mesalamine/ mesalazine","genericName":"MMX mesalamine/ mesalazine","slug":"mmx-mesalamine-mesalazine","indication":"Ulcerative colitis (induction and maintenance of remission)","status":"marketed"},{"name":"SPD476 (mesalazine)","genericName":"SPD476 (mesalazine)","slug":"spd476-mesalazine","indication":"Ulcerative colitis","status":"phase_3"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"SPD503 (3 mg)","genericName":"SPD503 (3 mg)","slug":"spd503-3-mg","indication":"Chronic obstructive pulmonary disease (COPD)","status":"phase_3"},{"name":"SPD503 (4 mg)","genericName":"SPD503 (4 mg)","slug":"spd503-4-mg","indication":"Chronic obstructive pulmonary disease (COPD)","status":"phase_3"},{"name":"SPD503 (1 mg)","genericName":"SPD503 (1 mg)","slug":"spd503-1-mg","indication":"Chronic obstructive pulmonary disease (COPD)","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"NPSP558","genericName":"NPSP558","slug":"npsp558","indication":"Acute decompensated heart failure","status":"phase_3"},{"name":"DX-2930","genericName":"DX-2930","slug":"dx-2930","indication":"Thrombotic disorders / thromboprophylaxis (Phase 3 development)","status":"phase_3"},{"name":"Saluron","genericName":"HYDROFLUMETHIAZIDE","slug":"hydroflumethiazide","indication":"Edema","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"infectious","drugs":[{"name":"SPD476 (4.8 g)","genericName":"SPD476 (4.8 g)","slug":"spd476-4-8-g","indication":"Type 2 diabetes","status":"phase_3"},{"name":"SHP615","genericName":"SHP615","slug":"shp615","indication":"Hypercholesterolemia","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"respiratory","drugs":[{"name":"ALX1-11 (drug)","genericName":"ALX1-11 (drug)","slug":"alx1-11-drug","indication":"Wnt-driven cancers (investigational)","status":"phase_3"}]},{"name":"Rare Disease","slug":"rare-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"metabolic","drugs":[{"name":"Replagal (agalsidase alfa)","genericName":"Replagal (agalsidase alfa)","slug":"replagal-agalsidase-alfa","indication":"Fabry disease (α-galactosidase A deficiency)","status":"marketed"}]}],"pipeline":[{"name":"SPD476 (1.2g)","genericName":"SPD476 (1.2g)","slug":"spd476-1-2g","phase":"phase_3","mechanism":"SPD476 is a small molecule drug that targets the molecular target.","indications":["Unknown"],"catalyst":""},{"name":"SPD503 (3 mg)","genericName":"SPD503 (3 mg)","slug":"spd503-3-mg","phase":"phase_3","mechanism":"SPD503 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels.","indications":["Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"ALX-0600","genericName":"ALX-0600","slug":"alx-0600","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ALX1-11","genericName":"ALX1-11","slug":"alx1-11","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Dynepo","genericName":"Dynepo","slug":"dynepo","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"NPSP558","genericName":"NPSP558","slug":"npsp558","phase":"phase_3","mechanism":"NPSP558 is a selective vasopressin V1a receptor antagonist that blocks vasopressin signaling to reduce aquaporin-2 water channel expression and increase urine output.","indications":["Acute decompensated heart failure","Hyponatremia"],"catalyst":""},{"name":"SPD476","genericName":"SPD476","slug":"spd476","phase":"phase_3","mechanism":"SPD476 is a small molecule drug that targets the serotonin receptor.","indications":["Treatment-resistant depression"],"catalyst":""},{"name":"SPD476 (4.8 g)","genericName":"SPD476 (4.8 g)","slug":"spd476-4-8-g","phase":"phase_3","mechanism":"SPD476 is a small molecule drug that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"SPD489","genericName":"SPD489","slug":"spd489","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SPD503 (4 mg)","genericName":"SPD503 (4 mg)","slug":"spd503-4-mg","phase":"phase_3","mechanism":"SPD503 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels.","indications":["Chronic obstructive pulmonary disease (COPD)","Asthma"],"catalyst":""},{"name":"SPD503-AM","genericName":"SPD503-AM","slug":"spd503-am","phase":"phase_3","mechanism":"SPD503-AM is a monoamine oxidase inhibitor that increases levels of dopamine, norepinephrine, and serotonin in the central nervous system.","indications":["Attention-deficit/hyperactivity disorder (ADHD)"],"catalyst":""},{"name":"SPD503-PM","genericName":"SPD503-PM","slug":"spd503-pm","phase":"phase_3","mechanism":"SPD503-PM is a small molecule drug that targets the serotonin receptor.","indications":["Obsessive-compulsive disorder","Major depressive disorder"],"catalyst":""},{"name":"Vpriv","genericName":"VELAGLUCERASE ALFA","slug":"velaglucerase-alfa","phase":"marketed","mechanism":"VELAGLUCERASE ALFA replaces the deficient enzyme glucocerebrosidase in patients with Gaucher's disease.","indications":["Chronic non-neuropathic Gaucher's disease"],"catalyst":""},{"name":"ALX1-11 (drug)","genericName":"ALX1-11 (drug)","slug":"alx1-11-drug","phase":"phase_3","mechanism":"ALX1-11 is a monoclonal antibody that blocks the Wnt signaling pathway by targeting Wnt ligands, thereby inhibiting aberrant cell proliferation and differentiation.","indications":["Wnt-driven cancers (investigational)"],"catalyst":""},{"name":"C1 Esterase Inhibitor (Human)","genericName":"C1 Esterase Inhibitor (Human)","slug":"c1-esterase-inhibitor-human","phase":"marketed","mechanism":"C1 esterase inhibitor (C1-INH) suppresses activation of the contact system and complement cascade by inhibiting plasma kallikrein and Factor XIIa, thereby reducing bradykinin generation and preventing angioedema attacks.","indications":["Hereditary angioedema (HAE) Types I and II — acute attack treatment","Hereditary angioedema — prophylaxis of recurrent attacks"],"catalyst":""},{"name":"C1 esterase inhibitor [human] liquid","genericName":"C1 esterase inhibitor [human] liquid","slug":"c1-esterase-inhibitor-human-liquid","phase":"phase_3","mechanism":"C1 esterase inhibitor replaces or augments the deficient or dysfunctional C1 inhibitor protein, which normally suppresses excessive activation of the contact system and complement cascade.","indications":["Hereditary angioedema (HAE) Types I and II — acute attack treatment and prophylaxis","Acquired angioedema (AAE) — acute attack treatment"],"catalyst":""},{"name":"C1 inhibitor (human) [C1 INH]","genericName":"C1 inhibitor (human) [C1 INH]","slug":"c1-inhibitor-human-c1-inh","phase":"marketed","mechanism":"C1 inhibitor (human) is a plasma protein that regulates the initial step of the classical complement cascade by inhibiting C1s protease activity.","indications":["Hereditary angioedema (HAE) — acute attack treatment","Hereditary angioedema (HAE) — prophylaxis of recurrent attacks"],"catalyst":""},{"name":"CINRYZE 1000","genericName":"CINRYZE 1000","slug":"cinryze-1000","phase":"phase_3","mechanism":"CINRYZE is a plasma kallikrein inhibitor that reduces bradykinin production to prevent acute attacks in hereditary angioedema.","indications":["Hereditary angioedema (HAE) — acute attack prevention and treatment"],"catalyst":""},{"name":"CINRYZE 1000 U","genericName":"CINRYZE 1000 U","slug":"cinryze-1000-u","phase":"phase_3","mechanism":"CINRYZE is a C1 esterase inhibitor (C1-INH) that replaces or augments deficient or dysfunctional C1 inhibitor protein to prevent excessive bradykinin generation and control hereditary angioedema attacks.","indications":["Hereditary angioedema (HAE) Types I and II — acute attack treatment and prophylaxis"],"catalyst":""},{"name":"CINRYZE 500","genericName":"CINRYZE 500","slug":"cinryze-500","phase":"phase_3","mechanism":"CINRYZE is a C1 esterase inhibitor (C1-INH) that suppresses activation of the contact system to prevent bradykinin-mediated angioedema attacks.","indications":["Hereditary angioedema (HAE) Types I and II — acute attack treatment and prophylaxis"],"catalyst":""},{"name":"CINRYZE 500 U","genericName":"CINRYZE 500 U","slug":"cinryze-500-u","phase":"phase_3","mechanism":"CINRYZE is a C1 esterase inhibitor (C1-INH) that replaces deficient or dysfunctional C1 inhibitor protein to prevent excessive bradykinin generation and control hereditary angioedema attacks.","indications":["Hereditary angioedema (HAE) Types I and II — acute attack treatment and prophylaxis"],"catalyst":""},{"name":"DX-2930","genericName":"DX-2930","slug":"dx-2930","phase":"phase_3","mechanism":"DX-2930 is a Factor XIIa inhibitor that reduces contact pathway activation to prevent thrombosis without affecting primary hemostasis.","indications":["Thrombotic disorders / thromboprophylaxis (Phase 3 development)"],"catalyst":""},{"name":"Delayed and extended release mesalazine","genericName":"Delayed and extended release mesalazine","slug":"delayed-and-extended-release-mesalazine","phase":"phase_3","mechanism":"Mesalazine (5-aminosalicylic acid) reduces intestinal inflammation by inhibiting prostaglandin and leukotriene production and scavenging reactive oxygen species in the colon.","indications":["Ulcerative colitis (induction and maintenance of remission)","Crohn's disease (colonic involvement)"],"catalyst":""},{"name":"Elaprase","genericName":"Elaprase","slug":"elaprase","phase":"marketed","mechanism":"Small molecule","indications":["Mucopolysaccharidosis, MPS-II"],"catalyst":""},{"name":"FST-100","genericName":"FST-100","slug":"fst-100","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Fosrenol (Lanthanum Carbonate)","genericName":"Fosrenol (Lanthanum Carbonate)","slug":"fosrenol-lanthanum-carbonate","phase":"phase_3","mechanism":"Lanthanum carbonate binds to phosphate in the gastrointestinal tract, forming insoluble complexes that are eliminated in feces, thereby reducing serum phosphate levels.","indications":["Hyperphosphatemia in patients with chronic kidney disease on dialysis","Hyperphosphatemia in patients with chronic kidney disease not on dialysis"],"catalyst":""},{"name":"HGT-1110","genericName":"HGT-1110","slug":"hgt-1110","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"MHOS/SHP615","genericName":"MHOS/SHP615","slug":"mhos-shp615","phase":"phase_3","mechanism":"MHOS/SHP615 is a long-acting growth hormone secretagogue (ghrelin receptor agonist) that stimulates growth hormone release.","indications":["Growth hormone deficiency in adults"],"catalyst":""},{"name":"MMX Mesalamine","genericName":"MMX Mesalamine","slug":"mmx-mesalamine","phase":"marketed","mechanism":"MMX Mesalamine is a delayed-release formulation of mesalamine that delivers the anti-inflammatory drug to the colon to reduce inflammation in inflammatory bowel disease.","indications":["Induction of remission of mild to moderate ulcerative colitis","Maintenance of remission of ulcerative colitis"],"catalyst":""},{"name":"MMX mesalamine/ mesalazine","genericName":"MMX mesalamine/ mesalazine","slug":"mmx-mesalamine-mesalazine","phase":"marketed","mechanism":"MMX mesalamine is an anti-inflammatory agent that reduces inflammation in the colon by inhibiting prostaglandin and leukotriene production.","indications":["Ulcerative colitis (induction and maintenance of remission)","Crohn's disease (colonic involvement)"],"catalyst":""},{"name":"PEG 4000","genericName":"PEG 4000","slug":"peg-4000","phase":"phase_3","mechanism":"PEG 4000 is an osmotic laxative that draws water into the intestinal lumen to soften stool and promote bowel movements.","indications":["Constipation","Bowel preparation prior to colonoscopy or other GI procedures"],"catalyst":""},{"name":"PTH/Calcium","genericName":"PTH/Calcium","slug":"pth-calcium","phase":"phase_3","mechanism":"This combination therapy works by supplementing parathyroid hormone (PTH) to regulate calcium homeostasis and bone metabolism.","indications":["Hypoparathyroidism","Post-surgical hypoparathyroidism"],"catalyst":""},{"name":"Phosphate Buffer Saline (PBS),","genericName":"Phosphate Buffer Saline (PBS),","slug":"phosphate-buffer-saline-pbs","phase":"phase_3","mechanism":"PBS is a buffered saline solution that maintains physiological pH and osmolarity, serving as a vehicle or diluent rather than an active pharmaceutical agent.","indications":[],"catalyst":""},{"name":"Replagal (agalsidase alfa)","genericName":"Replagal (agalsidase alfa)","slug":"replagal-agalsidase-alfa","phase":"marketed","mechanism":"Agalsidase alfa is a recombinant human enzyme that replaces deficient α-galactosidase A, breaking down accumulated globotriaosylceramide in cells.","indications":["Fabry disease (α-galactosidase A deficiency)"],"catalyst":""},{"name":"SHP615","genericName":"SHP615","slug":"shp615","phase":"phase_3","mechanism":"SHP615 is a monoclonal antibody targeting the PCSK9 protein.","indications":["Hypercholesterolemia"],"catalyst":""},{"name":"SPD476 (2.4 g)","genericName":"SPD476 (2.4 g)","slug":"spd476-2-4-g","phase":"phase_3","mechanism":"SPD476 is a monoamine oxidase inhibitor that increases levels of dopamine, norepinephrine, and serotonin in the central nervous system.","indications":["Major depressive disorder"],"catalyst":""},{"name":"SPD476 (mesalazine)","genericName":"SPD476 (mesalazine)","slug":"spd476-mesalazine","phase":"phase_3","mechanism":"SPD476 (mesalazine) works by inhibiting the enzyme aminopeptidase N to reduce inflammation in the gut.","indications":["Ulcerative colitis","Crohn's disease"],"catalyst":""},{"name":"SPD503 (1 mg)","genericName":"SPD503 (1 mg)","slug":"spd503-1-mg","phase":"phase_3","mechanism":"SPD503 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels.","indications":["Chronic obstructive pulmonary disease (COPD)","Asthma"],"catalyst":""},{"name":"SPD503 (2 mg)","genericName":"SPD503 (2 mg)","slug":"spd503-2-mg","phase":"phase_3","mechanism":"SPD503 is a dopamine receptor agonist.","indications":["Parkinson's disease"],"catalyst":""},{"name":"SPD503 (Guanfacine HCl)","genericName":"SPD503 (Guanfacine HCl)","slug":"spd503-guanfacine-hcl","phase":"phase_3","mechanism":"Guanfacine is an alpha-2A adrenergic receptor agonist that reduces norepinephrine activity in the prefrontal cortex to improve attention and impulse control.","indications":["Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents"],"catalyst":""},{"name":"Saluron","genericName":"HYDROFLUMETHIAZIDE","slug":"hydroflumethiazide","phase":"marketed","mechanism":"Solute carrier family 12 member 3","indications":["Edema","Hypertensive disorder"],"catalyst":""},{"name":"TED","genericName":"TED","slug":"ted","phase":"marketed","mechanism":"TED is a prodrug that is converted to active metabolites to treat attention-deficit/hyperactivity disorder (ADHD) by enhancing central nervous system stimulation.","indications":["Attention-deficit/hyperactivity disorder (ADHD)"],"catalyst":""},{"name":"lumbar puncture","genericName":"lumbar puncture","slug":"lumbar-puncture","phase":"phase_3","mechanism":"Lumbar puncture is a diagnostic procedure, not a drug, and does not have a pharmacological mechanism.","indications":[],"catalyst":""},{"name":"rhPTH (1-84)","genericName":"rhPTH (1-84)","slug":"rhpth-1-84","phase":"marketed","mechanism":"rhPTH (1-84) is a recombinant human parathyroid hormone that binds to PTH1 receptors on bone cells to stimulate bone formation and increase serum calcium and phosphate levels.","indications":["Hypoparathyroidism"],"catalyst":""},{"name":"tedguglutide","genericName":"tedguglutide","slug":"tedguglutide","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPTV9NWTFRU3pXQ3U0dDVQeGZCMlAzUlNKblZGTUpYbnQ3eWp2dFo5QXJKRG1RaWlTdkZ4SU5vQnRBbmNxNlN2MFF1R0txV2c0Yy1FYTNUV055d0F3Zm53YWQ3em5tdGxSUWMyeE5neGlfZldqN3pnanIzckUxY1hsZjdKSlMtR0N4NG45bGZmc05RWk9OdjFCbEtZeVpnRTAtenFScG9MZk9Mdzh2MmYwOXFoWEhReVk2Zzlr?oc=5","date":"2026-02-10","type":"trial","source":"Stock Titan","summary":"New Helus Pharma CEO inherits mental health drug pipeline at key trial dates - Stock Titan","headline":"New Helus Pharma CEO inherits mental health drug pipeline at key trial dates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQMndNQ09JM1NfOUtkYlV1SFk4RUlfUmp1S1BwcUItQUljV2VweURHRzJKQlBNb1hPekY2WWY3ZFR2UG5JZ2hHdUQ5TGxLV3kwNXNXcUFJYXI3bDFMME9PZjFYMVoyREY1c1UzVF9iN2ZKeE1weU9qWFVnd0paZWRCelFnXzNlLUZqcElVSlY1UVhtS3NFc1YwaE9yRHFmQQ?oc=5","date":"2025-04-22","type":"pipeline","source":"CNBC","summary":"How Takeda's CEO transformed the company into a global pharma powerhouse - CNBC","headline":"How Takeda's CEO transformed the company into a global pharma powerhouse","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE9aZUt5M09DelFXcXoyaW5JZ3VNdUhqeU5NamlQanlmeWtqMWRDMXRWVklZU0xBOU1MX3JjNVhFU0NfOHlfd095UWJDTndlTlhRRzRQX2ZCZno5TGhEcnFHcHJHNVlaY1YtZHZ0ZXdmNklTME02UVRjSHpMTkt0UQ?oc=5","date":"2024-01-19","type":"deal","source":"Pharma Voice","summary":"Five years after closing the Shire deal, Takeda is ready to harvest from its latest reinvention - Pharma Voice","headline":"Five years after closing the Shire deal, Takeda is ready to harvest from its latest reinvention","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNYnRLQ0ZjalpGTU5vS2R6YWl5dFhKazBoUjEwcVd5QndXeGhxWVJici1DanFuUHN1ZHE5TEhQX3Y1bEE5MWdtNzU2alpISEM5U01HNl82NFI2c1dXTUs0RF94RHRlamI0MXh5cGdxOWQ1RDJ5dW5jWTdnOFdpZEpldFZQTXJqOTdOLV82SEprZ2NhdThaMzBwb1d6ODM?oc=5","date":"2020-02-19","type":"pipeline","source":"takeda.com","summary":"Shire named \"Pharma Company of the Year\" by Scrip - takeda.com","headline":"Shire named \"Pharma Company of the Year\" by Scrip","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPVWxRc0tYNkRKTU45MHJuRDNPNDhpeENrczF1VE9aWDM2Nmo0bHVPUjNrVWZxTmhvaWRqVWRZWHkwTFl6cGJGMXRXQ2hHODM2bndILUlXdTJLLUJtemprZ1RQLThCc19OTDUwb0VUN0NIRDBNZkVUakpBUG9ranBKdXg0bmlOdWxHMUhsRVZzTHhKb0hKTTdBdDd6cUk3c1dtay1BWHR5dEhjWHh0Rmc?oc=5","date":"2019-09-02","type":"deal","source":"Pharmaceutical Technology","summary":"Takeda-Shire deal: the strategy behind Japan’s largest foreign acquisition - Pharmaceutical Technology","headline":"Takeda-Shire deal: the strategy behind Japan’s largest foreign acquisition","sentiment":"neutral"},{"date":"2019-02-15","type":"earnings","source":"SEC EDGAR","summary":"SC 13G filed with SEC: SC 13G","headline":"SC 13G Filing","sentiment":"neutral"},{"date":"2019-01-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPZ240T29hbXdxeU5Hc3diMWhQbExadWQ3UVlxdGd1dVRLZWNtTmRWS3RCc3VFSEtMV0ZJM1lPSm9talRhYkwwcnlyUS1oNWtZaXZoekY3cjg0bkVZY0I1MVJ6aGpyOTQxQ0prY01kLTlOVExuMElFcjUzZ3plQUtfV01OTUFGR2dlemNGLXA4RjRRVHRoaWlacEsyTGZhdm5SWHVKdlpwbWwxWXc?oc=5","date":"2019-01-09","type":"deal","source":"BioPharma Dive","summary":"Shire deal done, Takeda turns to task of forging top pharma - BioPharma Dive","headline":"Shire deal done, Takeda turns to task of forging top pharma","sentiment":"neutral"},{"date":"2019-01-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2019-01-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2019-01-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2019-01-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQckRLcmdWbHF3b3JqcGtxQ2dHdmJQc2pwZ3VZdEcteUI4Q0VNLXZ3bEplUnQteWh1YUNnbkNGSDBiNzZJRlAwZ3I2VWc5S2QzS1I1cEtXYzY3alRJci1hREdlZVE5VVd1b3VqYkM3RXEwNUVvTUFpQ1M3VjBIWTBIblozUkp5Y2RYV0NRQXFn?oc=5","date":"2018-06-05","type":"pipeline","source":"statnews.com","summary":"The 'cruel joke' of compassionate use and right to try: Pharma companies don't have to comply - statnews.com","headline":"The 'cruel joke' of compassionate use and right to try: Pharma companies don't have to comply","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNc2VaUXZOZlB3UENtMWsxS21taEJzUkhYekpVcURNYTJ6LW9qNjZyWmNUaHZCcjNDVlJGUlBPUkNobkxQN2FUblNKOVZNQU1HVi02ZUVDcW8wN3hYQXNFSzZUVWFVRm9aNUpsbkhZQXpzS2lKNllROWJqMWdUWXVWNU56c3RZb2RmUUVFZDEyTG9yWEJnM0FYdkRsaFVlZGpsTDA2X0g5QXZGMER3bi1XUnk2bmM5aHZWUVRYZl9Baw?oc=5","date":"2018-05-09","type":"deal","source":"Reuters","summary":"Japan's Takeda clinches $62 billion Shire deal as pharma M&A rolls on - Reuters","headline":"Japan's Takeda clinches $62 billion Shire deal as pharma M&A rolls on","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNZ1gydVl0REhpVlJLWVBhc0VQZmxkUlhtRVhtVElIX21KX0Jkd0JhYTF5X0pKME9zUEItTC1tN0lIRW9iZmI5OWo1V1FtNlNJNVU0UXBPQV9MODNJd01wRnI0RDJvTnFnRE5ZYk1WbnNaRkxIMkw2UUFRc3JpbmVZT0xFY2t1UVVfUGh2UDluZ1dkRmR1SjdDNm5wb0N1MTlmSHBBeEJnOU94WWNJcVE?oc=5","date":"2018-04-19","type":"pipeline","source":"WSJ","summary":"Fast-Growing Shire Had Pharmaceutical Rivals in a Takeover Frenzy - WSJ","headline":"Fast-Growing Shire Had Pharmaceutical Rivals in a Takeover Frenzy","sentiment":"neutral"}],"patents":[],"drugCount":45,"phaseCounts":{"phase_3":29,"phase_2":2,"marketed":12,"phase_1":2},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":15160600000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":15160600000,"period":"2017-12-31"},{"value":3697600000,"period":"2017-09-30"},{"value":3745800000,"period":"2017-06-30"},{"value":3572300000,"period":"2017-03-31"},{"value":11396600000,"period":"2016-12-31"},{"value":3452100000,"period":"2016-09-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":1763300000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":4271500000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":472400000,"cashHistory":[],"totalAssets":67756900000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}